Sanofi: positive results for Praluent.
(CercleFinance.com) - Sanofi and Regeneron Pharmaceuticals have announced positive results of two phase 3b 4 ODYSSEY-DM clinical trials, the first studies to evaluate Praluent (alirocumab) in people with diabetes and hypercholesterolemia.
Tests have shown that the product, in combination with statins at the maximum tolerated dose, significantly reduces cholesterol in low density lipoproteins (LDL-C), the main assessment criterion of the ODYSSEY-DM-INSULIN study.
Likewise, the effect on the reduction of cholesterol levels in non-high density lipoproteins (non-HDL-C), the main assessment criterion of the ODYSSEY-DM-DYSLIPIDEMIA study, is superior to the usual treatment.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Tests have shown that the product, in combination with statins at the maximum tolerated dose, significantly reduces cholesterol in low density lipoproteins (LDL-C), the main assessment criterion of the ODYSSEY-DM-INSULIN study.
Likewise, the effect on the reduction of cholesterol levels in non-high density lipoproteins (non-HDL-C), the main assessment criterion of the ODYSSEY-DM-DYSLIPIDEMIA study, is superior to the usual treatment.
Copyright (c) 2017 CercleFinance.com. All rights reserved.